Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis
Stopped Due to change in Sanofi's development strategy for DNL747/SAR443060 - not due to any safety concerns
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
- DRUG: DNL747
- DRUG: Placebo
Sponsor
Sanofi
Collaborators